Whistleblowers, Undercover Employees Wearing Wires Led To Johnson & Johnson’s Guilty Plea Involving Risperdal

As reported earlier, Johnson & Johnson will pay $2.2 billion due to its practices of improper marketing and failure to warn.  Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, admitted that it promoted Risperdal to health care providers for treatment of psychotic symptoms and associated behavioral disturbances exhibited by elderly, non-schizophrenic dementia patients. More facts [...]

November 12th, 2013|Drug and Medical Device Litigation|0 Comments

Johnson & Johnson Pleads Guilty to Criminal Charges and is Fined $2.2 Billion for Improperly Marketing Risperdal

Janssen Pharmaceuticals, Inc. (JPI), a Johnson and Johnson company, has pled guilty to claims stemming from allegations that the giant pharmaceutical company knowingly marketed the anti-psychotic drug Risperdal for inappropriate uses and paid kickbacks to doctors and nursing homes in prescribing the drug.  JPI will plead guilty to one misdemeanor violation of the Food Drug [...]

November 5th, 2013|Drug and Medical Device Litigation|0 Comments